Pulike Biological Engineering Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Wei Hu

Chief executive officer

CN¥2.6m

Total compensation

CEO salary percentage	n/a
CEO tenure	13.7yrs
CEO ownership	1.2%
Management average tenure	no data
Board average tenure	7.5yrs

Recent management updates

Recent updates

Pulike Biological Engineering's (SHSE:603566) Weak Earnings May Only Reveal A Part Of The Whole Picture

Sep 04

Pulike Biological Engineering, Inc. (SHSE:603566) Looks Just Right With A 34% Price Jump

May 21

Need To Know: The Consensus Just Cut Its Pulike Biological Engineering, Inc. (SHSE:603566) Estimates For 2024

Apr 28

Why Investors Shouldn't Be Surprised By Pulike Biological Engineering, Inc.'s (SHSE:603566) Low P/E

Mar 21

Pulike Biological Engineering (SHSE:603566) Seems To Use Debt Quite Sensibly

Feb 28

CEO

Wei Hu (51 yo)

13.7yrs

Tenure

CN¥2,634,900

Compensation

Mr. Wei Hu is Director of Pulike Biological Engineering, Inc. since March 26, 2011 and serves as its Managing Director. Mr. Hu was Deputy General Manager and Non-Independent Director of Pulike Biological E...

Board Members

Name	Position	Tenure	Compensation	Ownership
Wei Hu	MD & Director	13.7yrs	CN¥2.63m	1.22% CN¥ 54.4m
Lian Feng Pei	CFO, Accounting Supervisor & Director	13.7yrs	CN¥1.05m	0.40% CN¥ 17.9m
Yong Jun Song	Deputy GM & Non-Independent Director	13.7yrs	CN¥1.17m	0.88% CN¥ 39.0m
Rui Zhao	Secretary of the Board & Director	8.5yrs	CN¥854.80k	0.0066% CN¥ 291.1k
Xian Sheng Zhang	Independent Director	1.6yrs	CN¥61.10k	no data
Xu Ke Zhang	Chairman of the Board	13.7yrs	CN¥1.19m	31.97% CN¥ 1.4b
Dechao Qin	Vice Chairman	7.5yrs	CN¥2.63m	0.058% CN¥ 2.6m
Chuduan Wang	Independent Director	1.6yrs	CN¥61.10k	no data
Xiaoli Wang	Supervisor	1.6yrs	no data	0.0027% CN¥ 121.3k
Yongchang Cao	Independent Director	1.6yrs	no data	no data
Dongjuan Yuan	Employee Representative Supervisor	1.6yrs	no data	no data

7.5yrs

Average Tenure

53yo

Average Age

Experienced Board: 603566's board of directors are considered experienced (7.5 years average tenure).

Pulike Biological Engineering Management

Management criteria checks 1/4

Key information

Recent management updates

Less than half of directors are independent

Pulike Biological Engineering, Inc., Annual General Meeting, May 16, 2024

Recent updates

New minor risk - Earnings quality

Less than half of directors are independent

New minor risk - Profit margin trend

Pulike Biological Engineering, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 17%

Now 21% undervalued after recent price drop

Pulike Biological Engineering's (SHSE:603566) Weak Earnings May Only Reveal A Part Of The Whole Picture

Price target decreased by 13% to CN¥16.24

Now 22% undervalued after recent price drop

Price target decreased by 8.3% to CN¥18.56

Pulike Biological Engineering, Inc. to Report First Half, 2024 Results on Aug 30, 2024

Dividend of CN¥0.40 announced

Investor sentiment deteriorates as stock falls 20%

Pulike Biological Engineering, Inc. (SHSE:603566) Looks Just Right With A 34% Price Jump

Investor sentiment improves as stock rises 19%

Now 26% overvalued after recent price rise

Consensus revenue estimates fall by 13%

Need To Know: The Consensus Just Cut Its Pulike Biological Engineering, Inc. (SHSE:603566) Estimates For 2024

First quarter 2024 earnings released: EPS: CN¥0.08 (vs CN¥0.19 in 1Q 2023)

Pulike Biological Engineering, Inc., Annual General Meeting, May 16, 2024

Pulike Biological Engineering, Inc. to Report Q1, 2024 Results on Apr 26, 2024

Why Investors Shouldn't Be Surprised By Pulike Biological Engineering, Inc.'s (SHSE:603566) Low P/E

Price target decreased by 8.0% to CN¥25.07

Pulike Biological Engineering (SHSE:603566) Seems To Use Debt Quite Sensibly

Investor sentiment deteriorates as stock falls 15%

Pulike Biological Engineering, Inc. to Report Fiscal Year 2023 Results on Apr 26, 2024

Pulike Biological Engineering, Inc. (SHSE:603566) announces an Equity Buyback for CNY 200 million worth of its shares.

Pulike Biological Engineering, Inc. (SHSE:603566) announces an Equity Buyback for CNY 200 million worth of its shares.

Pulike Biological Engineering, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Price target decreased by 7.9% to CN¥28.23

New major risk - Earnings quality

Pulike Biological Engineering, Inc. to Report First Half, 2023 Results on Aug 30, 2023

Consensus EPS estimates fall by 11%

First quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.12 in 1Q 2022)

Price target decreased to CN¥28.05

Consensus forecasts updated

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.21 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.24 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥22.55

Investor sentiment improved over the past week

Price target decreased to CN¥26.37

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.13 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.20 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.18 in 1Q 2020)

New 90-day low: CN¥20.02

Full year 2020 earnings released: EPS CN¥0.68 (vs CN¥0.34 in FY 2019)

Revenue and earnings beat expectations

New 90-day low: CN¥20.15

New 90-day low: CN¥21.50

New 90-day low: CN¥23.20

New 90-day low: CN¥23.82

Third quarter earnings released

New 90-day high - CN¥31.00

First half earnings released

New 90-day high - CN¥29.65

Pulike Biological Engineering, Inc. to Report First Half, 2020 Results on Aug 31, 2020

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age